ArticleJournal of racial and ethnic health disparities2026
Disparities in time to Treatment Initiation Among Patients with Major Types of Cancer in the United States.
Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe current study aims to understand potential disparities in the time to treatment initiation among individuals diagnosed with one of the four most common cancers in the United States and dissect potential changes in time to treatment over time.
methodsThe Surveillance, Epidemiology, and End Results (SEER) database was accessed, and cases with a primary diagnosis of lung, colorectal, breast, or prostate cancer and a known time between diagnosis and treatment initiation were reviewed. Frequency analyses to examine mean time to treatment initiation across different years within each cancer type were performed, and multivariable logistic regression analyses were then conducted to evaluate factors associated with longer time to treatment within each cancer type.
resultsFor each of the four cohorts, diagnosis in the year 2021 was associated with the longest mean time to start treatment (47.49 days for the lung cancer cohort; 26.38 days for the colorectal cancer cohort; 44.61 days for the breast cancer cohort; 82.75 days for prostate cancer cohort). Within multivariable logistic regression analysis, non-white race was associated with longer time to treatment in each of the studied cancers; for lung cancer cohort: (OR black vs. white race: 1.254 (95% CI: 1.213–1.296); OR Asian/Pacific Islander vs. White race 1.168 (95% CI: 1.125–1.213)); for colorectal cancer cohort: (OR Black vs. white race: 1.057 (95% CI: 1.021–1.094); OR American Indian vs. White race 1.191 (95% CI: 1.068–1.327); OR Asian/Pacific Islander vs. White race 1.117 (95% CI: 1.076–1.159)); for breast cancer cohort (OR for black vs. white race: 1.155 (95%CI: 1.128–1.184)); OR for American Indian vs. White race: 1.134 (95% CI: 1.037–1.241)); OR for Asian/Pacific Islander vs. White race: 1.092 (95% CI: 1.065–1.119)); for prostate cancer cohort ((OR black race vs. white race: 1.239 (95% CI: 1.196–1.285)); OR Asian/Pacific Islander vs. white race: 1.219 (95% CI: 1.157–1.284)).
conclusionsCancer patients with non-white race are likely to have a delayed time to initiation of treatment, across major cancer types in the United States. This disparity was maintained even during the COVID-19 pandemic-related healthcare system distress.
Indexed as
Identifiers
41591736What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.